Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $54.00 and last traded at $54.00, with a volume of 100 shares. The stock had previously closed at $52.83.
Basilea Pharmaceutica Stock Performance
The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10. The firm’s 50 day simple moving average is $52.88 and its 200 day simple moving average is $52.58.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Energy Transfer: Powering Data With Dividends and Diversification
- What is diluted earnings per share (Diluted EPS)?
- Qualcomm Stock Is Coiling for a Breakout
- What is the Australian Securities Exchange (ASX)
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
